Open | - |
Close | - |
Volume / Avg. | 7.301K / 2.526M |
Day Range | - - - |
52 Wk Range | 0.490 - 2.050 |
Market Cap | $397.807M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 68 |
Short Interest | 3.86% |
Days to Cover | 4.82 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Akebia Therapeutics (NASDAQ: AKBA) through any online brokerage.
Other companies in Akebia Therapeutics’s space includes: Renovaro (NASDAQ:RENB), Humacyte (NASDAQ:HUMA), Adverum Biotechnologies (NASDAQ:ADVM), Precigen (NASDAQ:PGEN) and Inozyme Pharma (NASDAQ:INZY).
The latest price target for Akebia Therapeutics (NASDAQ: AKBA) was reported by HC Wainwright & Co. on Friday, March 15, 2024. The analyst firm set a price target for 5.00 expecting AKBA to rise to within 12 months (a possible 163.16% upside). 15 analyst firms have reported ratings in the last year.
The stock price for Akebia Therapeutics (NASDAQ: AKBA) is $1.9 last updated Today at March 19, 2024 at 7:08 AM EDT.
There are no upcoming dividends for Akebia Therapeutics.
Akebia Therapeutics’s Q1 earnings are confirmed for Monday, May 6, 2024.
There is no upcoming split for Akebia Therapeutics.
Akebia Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.